is glp-1 patented Looming drug patent expirations draw generics firms The Heavy Price of GLP-1

CHAC1: a master regulator of oxidative stress and ferroptosis in human diseases and cancers

It's a challenging landscape, and were all trying to keep up

What makes an implant case complex Not all implants are created equal

Healthcare providers should take patient reports of fatigue seriously and conduct appropriate evaluation to determine the underlying cause

We chose SGLT-2 inhibitors as the secondary comparator because they are also used at a disease stage similar to GLP-1 receptor agonists and have not been associated with the outcome.16 For both cohorts, we defined cohort entry as the date of the first prescription for either a GLP-1 receptor agonist or the comparator drug during the study period